Horizon Pharma, Inc. Announces Results Of Phase 3 Study Of LODOTRA® Demonstrate 12-Month Sustained Efficacy And Safety …

Horizon Pharma, Inc. Announces Results Of Phase 3 Study Of LODOTRA® Demonstrate 12-Month Sustained Efficacy And Safety …
Horizon Pharma, Inc. announced the results from the extended open label portion of The Circadian Administration of Prednisone in Rheumatoid Arthritis-1 (CAPRA-1) Phase 3 European registration study of LODOTRA®, a programmed release formulation of low-dose prednisone, which showed sustained improvement in reducing the duration of morning stiffness in patients with Rheumatoid Arthritis (RA) over a …
Read more on Medical News Today

Horizon Pharma’s phase 3 study of Lodotra demonstrates 12 month sustained efficacy & safety in RA
Horizon Pharma, Inc announced results from the extended open label portion of The Circadian Administration of Prednisone in Rheumatoid Arthritis-1 (CAPRA-1) phase-3 European registration study of Lodotra, a programmed release formulation of low-dose prednisone, which showed sustained improvement in reducing the duration of morning stiffness in patients with Rheumatoid Arthritis (RA) over a 12 …
Read more on PharmaBiz

Cinnamon for good health, say scientists
Inclusion of cinnamon in your daily diet makes for a healthy life, world scientists have confirmed.
Read more on Daily News

 Mail this post

Tags: 12Month - Announces - Demonstrate - Efficacy - Horizon - Inc. - LODOTRA® - Pharma - Phase - Results - Safety - Study - Sustained